Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
226 articles with Portola Pharmaceuticals, Inc.
The New England Journal of Medicine Publishes Results Of Portola’ Phase III ANNEXA Studies Of Andexanet Alfa
The New England Journal of Medicine Publishes Results Of Portola’ Phase 3 ANNEXA Studies Of Andexanet Alfa
Portola Announces Phase 3 ANNEXA-R Part 2 Study Results To Be Presented At American Heart Association Scientific Sessions 2015
Portola To Announce Third Quarter 2015 Financial Results And Host Conference Call On Monday, November 9
Portola Completes Enrollment In Pivotal Phase III APEX Study Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
Portola Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
Portola Announces Second Part Of Phase 3 ANNEXA-R Study: Andexanet Alfa And Rivaroxaban Meets Primary And Secondary Endpoints
Portola To Present Preclinical Data With Andexanet Alfa And Factor Xa Inhibitor Edoxaban At European Society of Cardiology Congress 2015
Portola To Announce Second Quarter 2015 Financial Results And Host Conference Call On Tuesday, August 4
Portola Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not
Portola Pharmaceuticals, Inc. Appoints Industry Leader Tao Fu As Executive Vice President, Chief Commercial And Business Officer
Portola Pharmaceuticals, Inc. Announces Upcoming Data Presentations On Andexanet Alfa At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress
Portola Pharmaceuticals, Inc. To Present At Goldman, Sachs & Co. 36th Annual Global Healthcare Conference
ASCO15: Portola Pharmaceuticals, Inc. Presents Updated Data From Ongoing Phase I/IIa Study Of Dual Kinase Inhibitor Cerdulatinib